LymphedemaV1, Pmc, Corpus, bibRecord, 002773

Health-Related Quality of Life in Long-Term Breast Cancer Survivors: Differences by Adjuvant Chemotherapy Dose in CALGB Study 8541

Identifieur interne : 002773 ( Pmc/Corpus ); précédent : 002772; suivant : 002774

Health-Related Quality of Life in Long-Term Breast Cancer Survivors: Differences by Adjuvant Chemotherapy Dose in CALGB Study 8541

Auteurs : Electra Paskett ; James Herndon ; Kathleen Donohue ; Michelle Naughton ; Stephen Grubbs ; Michael Pavy ; Martee Hensley ; Nancy Stark ; Alice Kornblith ; Marisa Bittoni

Source :

Cancer [ 0008-543X ] ; 2009.

RBID : PMC:2737348

Abstract

Background

The Survivor’s Health and Reaction (SHARE) study examined health-related quality of life (HRQL) in breast cancer patients who had participated in CALGB 8541 from 1985–1991.

Methods

A total of 245 survivors (78% of eligible patients) who were 9.4–16.5 years post-diagnosis (mean 12.5 years) completed HRQL surveys relating to 5 domains. Analyses examined HRQL domains by the three chemotherapy doses administered in the original treatment trial: low-dose=Cyclophosphamide/Doxorubicin/Flouracil (CAF) at 300/30/300×2 mg/m² over 4 cycles, standard-dose=CAF at 400/40/400×2 mg/m²over 4 cycles, and high-dose=CAF at 600/60/600 mg/m²over 4 cycles.

Results

In univariate analyses, a statistically significant difference was found in SF-36 physical role functioning by treatment group, with the standard treatment arm showing lower mean scores (mean=65.05) compared to the low-dose (mean=74.66) or high-dose (mean=84.94) arms (p=<0.0001). Multivariate analysis, however, revealed that treatment arm was no longer statistically significant, while the following factors were associated with decreased physical role functioning: age ≥60 (OR=3.55, p=0.006), increased comorbidity interference total score (OR=1.64, p=0.005), lower vitality (OR=1.05, p=0.0002) and increased menopausal symptoms (OR=1.04, p=0.02).

Conclusions

At 9.4–16.5 years post-diagnosis, differences in physical role functioning among breast cancer survivors who received three chemotherapy doses were explained by clinical and demographic variables, such as age, fatigue, menopausal symptoms and comorbidities. Prospective studies are needed to further assess the role of these factors in explaining HRQL and physical role functioning among long-term survivors.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737348

DOI: 10.1002/cncr.24140
PubMed: 19170232
PubMed Central: 2737348

Links to Exploration step

PMC:2737348

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Health-Related Quality of Life in Long-Term Breast Cancer Survivors: Differences by Adjuvant Chemotherapy Dose in CALGB Study 8541</title>
<author><name sortKey="Paskett, Electra" sort="Paskett, Electra" uniqKey="Paskett E" first="Electra" last="Paskett">Electra Paskett</name>
<affiliation><nlm:aff id="A1">The Ohio State University Comprehensive Cancer Center, Columbus, OH, supported by CA77658</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Herndon, James" sort="Herndon, James" uniqKey="Herndon J" first="James" last="Herndon">James Herndon</name>
<affiliation><nlm:aff id="A2">CALGB Statistical Center, Duke University Medical Center, Durham, NC, supported by CA33601</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Donohue, Kathleen" sort="Donohue, Kathleen" uniqKey="Donohue K" first="Kathleen" last="Donohue">Kathleen Donohue</name>
<affiliation><nlm:aff id="A2">CALGB Statistical Center, Duke University Medical Center, Durham, NC, supported by CA33601</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Naughton, Michelle" sort="Naughton, Michelle" uniqKey="Naughton M" first="Michelle" last="Naughton">Michelle Naughton</name>
<affiliation><nlm:aff id="A3">Wake Forest University School of Medicine, Winston-Salem, NC, supported by CA03927</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Grubbs, Stephen" sort="Grubbs, Stephen" uniqKey="Grubbs S" first="Stephen" last="Grubbs">Stephen Grubbs</name>
<affiliation><nlm:aff id="A4">Helen F. Graham Cancer Center, Delaware Christiana Care CCOP, Newark, DE, supported by CA45418</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Pavy, Michael" sort="Pavy, Michael" uniqKey="Pavy M" first="Michael" last="Pavy">Michael Pavy</name>
<affiliation><nlm:aff id="A5">Southeast Cancer Control Consortium Inc. CCOP, Goldsboro, NC, supported by CA45808</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hensley, Martee" sort="Hensley, Martee" uniqKey="Hensley M" first="Martee" last="Hensley">Martee Hensley</name>
<affiliation><nlm:aff id="A6">Memorial Sloan-Kettering Cancer Center, New York, NY, supported by CA77651</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Stark, Nancy" sort="Stark, Nancy" uniqKey="Stark N" first="Nancy" last="Stark">Nancy Stark</name>
<affiliation><nlm:aff id="A3">Wake Forest University School of Medicine, Winston-Salem, NC, supported by CA03927</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kornblith, Alice" sort="Kornblith, Alice" uniqKey="Kornblith A" first="Alice" last="Kornblith">Alice Kornblith</name>
<affiliation><nlm:aff id="A7">Dana-Farber Cancer Institute, Boston, MA, supported by CA32291</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bittoni, Marisa" sort="Bittoni, Marisa" uniqKey="Bittoni M" first="Marisa" last="Bittoni">Marisa Bittoni</name>
<affiliation><nlm:aff id="A1">The Ohio State University Comprehensive Cancer Center, Columbus, OH, supported by CA77658</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">19170232</idno>
<idno type="pmc">2737348</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737348</idno>
<idno type="RBID">PMC:2737348</idno>
<idno type="doi">10.1002/cncr.24140</idno>
<date when="2009">2009</date>
<idno type="wicri:Area/Pmc/Corpus">002773</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002773</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Health-Related Quality of Life in Long-Term Breast Cancer Survivors: Differences by Adjuvant Chemotherapy Dose in CALGB Study 8541</title>
<author><name sortKey="Paskett, Electra" sort="Paskett, Electra" uniqKey="Paskett E" first="Electra" last="Paskett">Electra Paskett</name>
<affiliation><nlm:aff id="A1">The Ohio State University Comprehensive Cancer Center, Columbus, OH, supported by CA77658</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Herndon, James" sort="Herndon, James" uniqKey="Herndon J" first="James" last="Herndon">James Herndon</name>
<affiliation><nlm:aff id="A2">CALGB Statistical Center, Duke University Medical Center, Durham, NC, supported by CA33601</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Donohue, Kathleen" sort="Donohue, Kathleen" uniqKey="Donohue K" first="Kathleen" last="Donohue">Kathleen Donohue</name>
<affiliation><nlm:aff id="A2">CALGB Statistical Center, Duke University Medical Center, Durham, NC, supported by CA33601</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Naughton, Michelle" sort="Naughton, Michelle" uniqKey="Naughton M" first="Michelle" last="Naughton">Michelle Naughton</name>
<affiliation><nlm:aff id="A3">Wake Forest University School of Medicine, Winston-Salem, NC, supported by CA03927</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Grubbs, Stephen" sort="Grubbs, Stephen" uniqKey="Grubbs S" first="Stephen" last="Grubbs">Stephen Grubbs</name>
<affiliation><nlm:aff id="A4">Helen F. Graham Cancer Center, Delaware Christiana Care CCOP, Newark, DE, supported by CA45418</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Pavy, Michael" sort="Pavy, Michael" uniqKey="Pavy M" first="Michael" last="Pavy">Michael Pavy</name>
<affiliation><nlm:aff id="A5">Southeast Cancer Control Consortium Inc. CCOP, Goldsboro, NC, supported by CA45808</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hensley, Martee" sort="Hensley, Martee" uniqKey="Hensley M" first="Martee" last="Hensley">Martee Hensley</name>
<affiliation><nlm:aff id="A6">Memorial Sloan-Kettering Cancer Center, New York, NY, supported by CA77651</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Stark, Nancy" sort="Stark, Nancy" uniqKey="Stark N" first="Nancy" last="Stark">Nancy Stark</name>
<affiliation><nlm:aff id="A3">Wake Forest University School of Medicine, Winston-Salem, NC, supported by CA03927</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kornblith, Alice" sort="Kornblith, Alice" uniqKey="Kornblith A" first="Alice" last="Kornblith">Alice Kornblith</name>
<affiliation><nlm:aff id="A7">Dana-Farber Cancer Institute, Boston, MA, supported by CA32291</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bittoni, Marisa" sort="Bittoni, Marisa" uniqKey="Bittoni M" first="Marisa" last="Bittoni">Marisa Bittoni</name>
<affiliation><nlm:aff id="A1">The Ohio State University Comprehensive Cancer Center, Columbus, OH, supported by CA77658</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Cancer</title>
<idno type="ISSN">0008-543X</idno>
<idno type="eISSN">1097-0142</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title>
<p id="P1">The Survivor’s Health and Reaction (SHARE) study examined health-related quality of life (HRQL) in breast cancer patients who had participated in CALGB 8541 from 1985–1991.</p>
</sec>
<sec sec-type="methods" id="S2"><title>Methods</title>
<p id="P2">A total of 245 survivors (78% of eligible patients) who were 9.4–16.5 years post-diagnosis (mean 12.5 years) completed HRQL surveys relating to 5 domains. Analyses examined HRQL domains by the three chemotherapy doses administered in the original treatment trial: low-dose=Cyclophosphamide/Doxorubicin/Flouracil (CAF) at 300/30/300×2 mg/m<sup>2</sup>
 over 4 cycles, standard-dose=CAF at 400/40/400×2 mg/m<sup>2</sup>
over 4 cycles, and high-dose=CAF at 600/60/600 mg/m<sup>2</sup>
over 4 cycles.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">In univariate analyses, a statistically significant difference was found in SF-36 physical role functioning by treatment group, with the standard treatment arm showing lower mean scores (mean=65.05) compared to the low-dose (mean=74.66) or high-dose (mean=84.94) arms (p=<0.0001). Multivariate analysis, however, revealed that treatment arm was no longer statistically significant, while the following factors were associated with decreased physical role functioning: age ≥60 (OR=3.55, p=0.006), increased comorbidity interference total score (OR=1.64, p=0.005), lower vitality (OR=1.05, p=0.0002) and increased menopausal symptoms (OR=1.04, p=0.02).</p>
</sec>
<sec id="S4"><title>Conclusions</title>
<p id="P4">At 9.4–16.5 years post-diagnosis, differences in physical role functioning among breast cancer survivors who received three chemotherapy doses were explained by clinical and demographic variables, such as age, fatigue, menopausal symptoms and comorbidities. Prospective studies are needed to further assess the role of these factors in explaining HRQL and physical role functioning among long-term survivors.</p>
</sec>
</div>
</front>
</TEI>
<pmc article-type="research-article" xml:lang="EN"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
  <pmc-dir>properties manuscript</pmc-dir>
  <front><journal-meta><journal-id journal-id-type="nlm-journal-id">0374236</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2771</journal-id>
<journal-id journal-id-type="nlm-ta">Cancer</journal-id>
<journal-title>Cancer</journal-title>
<issn pub-type="ppub">0008-543X</issn>
<issn pub-type="epub">1097-0142</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">19170232</article-id>
<article-id pub-id-type="pmc">2737348</article-id>
<article-id pub-id-type="doi">10.1002/cncr.24140</article-id>
<article-id pub-id-type="manuscript">NIHMS89210</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Health-Related Quality of Life in Long-Term Breast Cancer Survivors: Differences by Adjuvant Chemotherapy Dose in CALGB Study 8541</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Paskett</surname>
<given-names>Electra</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Herndon</surname>
<given-names>James</given-names>
<suffix>II</suffix>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Donohue</surname>
<given-names>Kathleen</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Naughton</surname>
<given-names>Michelle</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Grubbs</surname>
<given-names>Stephen</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Pavy</surname>
<given-names>Michael</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Hensley</surname>
<given-names>Martee</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Stark</surname>
<given-names>Nancy</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Kornblith</surname>
<given-names>Alice</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Bittoni</surname>
<given-names>Marisa</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<on-behalf-of>for the Cancer and Leukemia Group B</on-behalf-of>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>
The Ohio State University Comprehensive Cancer Center, Columbus, OH, supported by CA77658</aff>
<aff id="A2"><label>2</label>
CALGB Statistical Center, Duke University Medical Center, Durham, NC, supported by CA33601</aff>
<aff id="A3"><label>3</label>
Wake Forest University School of Medicine, Winston-Salem, NC, supported by CA03927</aff>
<aff id="A4"><label>4</label>
Helen F. Graham Cancer Center, Delaware Christiana Care CCOP, Newark, DE, supported by CA45418</aff>
<aff id="A5"><label>5</label>
Southeast Cancer Control Consortium Inc. CCOP, Goldsboro, NC, supported by CA45808</aff>
<aff id="A6"><label>6</label>
Memorial Sloan-Kettering Cancer Center, New York, NY, supported by CA77651</aff>
<aff id="A7"><label>7</label>
Dana-Farber Cancer Institute, Boston, MA, supported by CA32291</aff>
<author-notes><corresp id="cor1">Send reprint requests to: Electra Paskett, Ph.D., Associate Director for Population Sciences, Director, Center for Population Health and Health Disparities, The Ohio State University Comprehensive Cancer Center, 320 West 10<sup>th</sup>
 Avenue, Starling Loving Hall A356, Columbus, OH 43210-1240, 614-293-7713 (fax), 614-293-5611, <email>electra.paskett@osumc.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>21</day>
<month>1</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="ppub"><day>1</day>
<month>3</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>1</day>
<month>3</month>
<year>2010</year>
</pub-date>
<volume>115</volume>
<issue>5</issue>
<fpage>1109</fpage>
<lpage>1120</lpage>
<abstract><sec id="S1"><title>Background</title>
<p id="P1">The Survivor’s Health and Reaction (SHARE) study examined health-related quality of life (HRQL) in breast cancer patients who had participated in CALGB 8541 from 1985–1991.</p>
</sec>
<sec sec-type="methods" id="S2"><title>Methods</title>
<p id="P2">A total of 245 survivors (78% of eligible patients) who were 9.4–16.5 years post-diagnosis (mean 12.5 years) completed HRQL surveys relating to 5 domains. Analyses examined HRQL domains by the three chemotherapy doses administered in the original treatment trial: low-dose=Cyclophosphamide/Doxorubicin/Flouracil (CAF) at 300/30/300×2 mg/m<sup>2</sup>
 over 4 cycles, standard-dose=CAF at 400/40/400×2 mg/m<sup>2</sup>
over 4 cycles, and high-dose=CAF at 600/60/600 mg/m<sup>2</sup>
over 4 cycles.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">In univariate analyses, a statistically significant difference was found in SF-36 physical role functioning by treatment group, with the standard treatment arm showing lower mean scores (mean=65.05) compared to the low-dose (mean=74.66) or high-dose (mean=84.94) arms (p=<0.0001). Multivariate analysis, however, revealed that treatment arm was no longer statistically significant, while the following factors were associated with decreased physical role functioning: age ≥60 (OR=3.55, p=0.006), increased comorbidity interference total score (OR=1.64, p=0.005), lower vitality (OR=1.05, p=0.0002) and increased menopausal symptoms (OR=1.04, p=0.02).</p>
</sec>
<sec id="S4"><title>Conclusions</title>
<p id="P4">At 9.4–16.5 years post-diagnosis, differences in physical role functioning among breast cancer survivors who received three chemotherapy doses were explained by clinical and demographic variables, such as age, fatigue, menopausal symptoms and comorbidities. Prospective studies are needed to further assess the role of these factors in explaining HRQL and physical role functioning among long-term survivors.</p>
</sec>
</abstract>
<kwd-group><kwd>breast cancer</kwd>
<kwd>survivorship</kwd>
<kwd>quality of life</kwd>
<kwd>chemotherapy</kwd>
</kwd-group>
<contract-num rid="AG1">R01 AG016602-04
				||AG</contract-num>
<contract-sponsor id="AG1">National Institute on Aging  : NIA</contract-sponsor>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002773 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002773 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:2737348
   |texte=   Health-Related Quality of Life in Long-Term Breast Cancer Survivors: Differences by Adjuvant Chemotherapy Dose in CALGB Study 8541
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:19170232" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Health-Related Quality of Life in Long-Term Breast Cancer Survivors: Differences by Adjuvant Chemotherapy Dose in CALGB Study 8541

Health-Related Quality of Life in Long-Term Breast Cancer Survivors: Differences by Adjuvant Chemotherapy Dose in CALGB Study 8541

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki